Empliciti Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing multiple myeloma incidence, limited efficacy of traditional chemotherapy, early success of monoclonal antibody drugs, expansion of oncology treatment centers, rising investment in cancer research.

The growth in the forecast period can be attributed to growing adoption of immunotherapy protocols, expanding pipeline of monoclonal antibodies, increasing survival rates driving long term treatment demand, favorable reimbursement for oncology biologics, advancements in immune based drug development. Major trends in the forecast period include combination monoclonal antibody therapies, immune system targeted cancer treatments, shift toward personalized multiple myeloma care, rising use of immunotherapy in oncology, growing adoption of long term biologic regimens.

The increasing prevalence of multiple myeloma is expected to drive the growth of the empliciti market in the coming years. Multiple myeloma is a cancer of the plasma cells, a type of white blood cell found in the bone marrow, which results in abnormal cell growth and can damage bones, kidneys, and the immune system. The rising incidence of multiple myeloma is influenced by factors such as an aging population and improved diagnostic methods. Empliciti targets the SLAMF7 protein on myeloma and natural killer (NK) cells, enhancing the immune system’s ability to detect and eliminate cancer cells. It boosts NK cell activity and promotes antibody-dependent cellular cytotoxicity (ADCC), helping to slow disease progression when used alongside other treatments. For instance, in August 2024, the American Cancer Society reported that approximately 35,780 new cases of multiple myeloma were diagnosed in the United States, including 19,520 in men and 16,260 in women, with around 12,540 deaths expected, comprising 7,020 in men and 5,520 in women. Therefore, the rising prevalence of multiple myeloma is supporting the growth of the empliciti market.

Rising healthcare expenditure is also expected to drive the growth of the empliciti market in the coming years. Healthcare expenditure encompasses all spending on medical services, treatments, equipment, infrastructure, and personnel. Factors contributing to increased spending include an aging population, higher prevalence of chronic diseases, advancements in medical technology, and growing demand for improved healthcare services. Higher healthcare expenditure enables greater investment in advanced cancer therapies like Empliciti, facilitating broader access to innovative treatments, enhancing healthcare infrastructure, and supporting research for better cancer care outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, a notable acceleration compared to the 0.9% growth in 2022. Therefore, rising healthcare expenditure is expected to support the growth of the empliciti market.

The growing demand for targeted cancer therapies is also significantly driving the growth of the empliciti market. Targeted therapies aim to attack cancer cells by focusing on specific molecular markers, reducing damage to healthy cells. Demand for such therapies is rising due to advancements in precision medicine, increasing cancer prevalence, improved treatment efficacy, and a focus on minimizing side effects. Empliciti targets SLAMF7, a protein on multiple myeloma and immune cells, enhancing immune system activity to attack cancer while sparing healthy tissues. For instance, in June 2024, the Royal College of Radiologists, a UK-based professional body for clinical oncology and radiology, reported that in 2023, the demand for systemic anti-cancer therapies (SACT), including chemotherapy, grew by 6-8%. Consequently, the rising demand for targeted cancer therapies is expected to propel the growth of the empliciti market.

Major companies operating in the empliciti market are Bristol-Myers Squibb Company.

North America was the largest region in the empliciti market in 2025. The regions covered in the empliciti market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the empliciti market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the empliciti market by increasing costs associated with imported biologic inputs, advanced manufacturing equipment, and cold chain logistics. These cost pressures affect hospital pharmacies and oncology clinics, particularly in regions reliant on cross border pharmaceutical supply such as Asia Pacific and parts of Europe. Higher tariffs can influence treatment pricing and procurement timelines. At the same time, tariffs are encouraging localized biologics manufacturing and regional sourcing strategies. This is supporting long term supply chain resilience in oncology therapeutics.

The empliciti market research report is one of a series of new reports that provides empliciti market statistics, including empliciti industry global market size, regional shares, competitors with a empliciti market share, detailed empliciti market segments, market trends and opportunities, and any further data you may need to thrive in the empliciti industry. This empliciti market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Empliciti (elotuzumab) is a prescription medication used to treat multiple myeloma, a cancer affecting plasma cells in the bone marrow. It is a monoclonal antibody that works by targeting cancer cells and enhancing the immune system’s ability to fight them.

The primary indications for empliciti are active multiple myeloma and smoldering multiple myeloma. Active myeloma is a progressing blood cancer characterized by CRAB criteria, which can damage bones, red blood cells, kidneys, or involve myeloma-defining events identified through predictive markers or imaging. The drug belongs to various classes, including monoclonal antibodies, immunomodulatory agents, and proteasome inhibitors. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by hospitals, clinics, ambulatory care facilities, and home care settings.

The empliciti market consists of sales of combination therapies, and injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.